No new evidence identified to support changes to the 2016 recommendation against routine serologic screening for genital herpes<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n \n\tTUESDAY, Aug. 16, 2022 (HealthDay News) — The U.S. Preventive Services Task Force (USPSTF) did not find new evidence that could result in a change to the 2016 recommendation on screening for genital herpes and consequently continues to recommend against routine serologic screening. This conclusion forms the basis of a draft recommendation statement published online Aug. 16.\n<\/p>\n \n\tGary N. Asher, M.D., M.P.H., from RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center in Research Triangle Park, and colleagues dually reviewed 3,119 abstracts and 64 full-text articles against a priori eligibility criteria to identify evidence that could result in a change in the 2016 USPSTF D recommendation for herpes simplex virus 2 (HSV-2) screening. The researchers did not identify any new eligible studies on the benefits or harms of HSV-2 serologic screening, accuracy of available HSV-2 serologic tests, or preventive interventions that could be used in asymptomatic individuals who are seropositive for HSV-2 to reduce morbidity and transmission of genital herpes. Foundational evidence that informed the 2016 recommendation indicated a high-rate of false-positive test results and potential psychosocial harms associated with serologic screening for genital herpes.\n<\/p>\n \n\tBased on these findings, the USPSTF continues to recommend against routine serologic screening for genital herpes simplex virus infection in asymptomatic adolescents and adults, including pregnant persons (D recommendation).\n<\/p>\n \n\tThe draft recommendation statement and draft evidence review have been published for public comment. Comments can be submitted from Aug. 16 to Sept. 12, 2022.<\/p>\n Draft Evidence Review<\/a><\/p>\n Draft Recommendation Statement<\/a><\/p>\n